产品描述
| 溶解性 | DMSO |
| 存贮条件 | 储存温度-20°C |
| 生化机理 |
Radezolid (INN, codenamed RX-1741) is a novel oxazolidinone antibiotic being developed by Rib-X Pharmaceuticals, Inc. for the treatment of serious multi-drug–resistant infections. Radezolid has completed two phase-II clinical trials. One of these clinical trials was for uncomplicated skin and skin-structure infections (uSSSI) and the other clinical trial was for community acquired pneumonia (CAP). From Wikipedia |
| 别名 | ; |
